TargetEpidermal growth factor receptor [L858R](Homo sapiens (Human))
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 0.400nMAssay Description:The object of this assay was to test the inventive compounds for the kinase inhibitory activity in vitro. In this assay, an isotopic labeling method ...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 1nMAssay Description:The object of this assay was to test the inventive compounds for the kinase inhibitory activity in vitro. In this assay, an isotopic labeling method ...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor [T790M,L858R](Homo sapiens (Human))
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 1nMAssay Description:The object of this assay was to test the inventive compounds for the kinase inhibitory activity in vitro. In this assay, an isotopic labeling method ...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 4nMAssay Description:Inhibition of human recombinant EGFR by radiometric kinase assayMore data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 4nMAssay Description:Inhibition of human recombinant EGFR by radiometric kinase assayMore data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 400nMAssay Description:Inhibition of EGFR in human NCI-H1975 cells assessed as reduction in ERK phosphorylation incubated for 8 hrs by Western blotting methodMore data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataIC50: 400nMAssay Description:Inhibition of EGFR in human NCI-H1975 cells assessed as reduction in AKT phosphorylation incubated for 8 hrs by Western blotting methodMore data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang)
US Patent
Affinity DataKd: 0.600nMAssay Description:Binding affinity to wild type EGFR by KINOMEscan kinase binding assayMore data for this Ligand-Target Pair